Obesity Pharmacotherapy in Patients With Type 2 Diabetes

IN BRIEF Patients with obesity and type 2 diabetes are key targets for weight loss. Given the lack of behavioral weight loss in most patients, obesity pharmacotherapy options should be considered in this patient population. This article reviews key pharmacotherapy options for patients with coexistin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahan, Scott, Fujioka, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2017
Materias:
From Research to Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687110/
https://www.ncbi.nlm.nih.gov/pubmed/29151715
http://dx.doi.org/10.2337/ds17-0044
_version_ 1783278906178011136
author Kahan, Scott
Fujioka, Ken
author_facet Kahan, Scott
Fujioka, Ken
author_sort Kahan, Scott
collection PubMed
description IN BRIEF Patients with obesity and type 2 diabetes are key targets for weight loss. Given the lack of behavioral weight loss in most patients, obesity pharmacotherapy options should be considered in this patient population. This article reviews key pharmacotherapy options for patients with coexisting obesity and type 2 diabetes. Diabetes medications that are associated with weight gain should be avoided in these patients if possible.
format Online
Article
Text
id pubmed-5687110
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-56871102018-11-01 Obesity Pharmacotherapy in Patients With Type 2 Diabetes Kahan, Scott Fujioka, Ken Diabetes Spectr From Research to Practice IN BRIEF Patients with obesity and type 2 diabetes are key targets for weight loss. Given the lack of behavioral weight loss in most patients, obesity pharmacotherapy options should be considered in this patient population. This article reviews key pharmacotherapy options for patients with coexisting obesity and type 2 diabetes. Diabetes medications that are associated with weight gain should be avoided in these patients if possible. American Diabetes Association 2017-11 /pmc/articles/PMC5687110/ /pubmed/29151715 http://dx.doi.org/10.2337/ds17-0044 Text en © 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0 for details.
spellingShingle From Research to Practice
Kahan, Scott
Fujioka, Ken
Obesity Pharmacotherapy in Patients With Type 2 Diabetes
title Obesity Pharmacotherapy in Patients With Type 2 Diabetes
title_full Obesity Pharmacotherapy in Patients With Type 2 Diabetes
title_fullStr Obesity Pharmacotherapy in Patients With Type 2 Diabetes
title_full_unstemmed Obesity Pharmacotherapy in Patients With Type 2 Diabetes
title_short Obesity Pharmacotherapy in Patients With Type 2 Diabetes
title_sort obesity pharmacotherapy in patients with type 2 diabetes
topic From Research to Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687110/
https://www.ncbi.nlm.nih.gov/pubmed/29151715
http://dx.doi.org/10.2337/ds17-0044
work_keys_str_mv AT kahanscott obesitypharmacotherapyinpatientswithtype2diabetes
AT fujiokaken obesitypharmacotherapyinpatientswithtype2diabetes

Ejemplares similares